



EBF – ADC Training Day

Bringing ADC into practice

20 June 2017, Lisbon

The Altis Grand Hotel, Lisbon, Portugal

The EBF acknowledges the ADC experts from the AAPS LBA FWG for their advice and support in the preparation of the meeting.

07:30 08.45 - 09.00	Registration desk opens Welcome and introduction
09:00 – 10.30	Defining a bioanalytical strategy for ADCs or 'what do I measure for ADCs and why?'
09:00 - 09:30	Complexity and inter-modality nature of Antibody drug conjugates -
	Speaker: Surinder Kaur (Genentech)
09:30 - 10:00	Development phase bioanalytical strategy approach to Bioanalysis of ADCs from Discovery to Late Non-clinical to Clinical support - Speaker: Boris Gorovits (Pfizer)
10:00 - 10:30	Analyte diversity required for appropriate description of ADC PK Speaker: Surinder Kaur (Genentech)
10:30 - 11:00	Coffee break & networking
11:00– 12:30 11:00 - 11:45	Technology or 'how do I measure ADCs? ADC BA: Challenges and opportunities when using Ligand Binding Assay platform, including assay development and validation Speaker: Sarah Childs (GlaxoSmithKline)
11:45- 12:30	ADC BA: Challenges and opportunities when using LCMS platform, including assay development and validation Speaker: Rand Jenkins (PPDi)
12:30 - 13:30	Lunch
13:30 – 14:45	Does theory match practice?
13:30 – 14:15	ADCs, what is industry doing today? An overview. Speaker: Joe Stanta (Covance)
13:30 – 14:15 14:15 – 14:45	
	Speaker: Joe Stanta (Covance) Correlation between LBA and hybrid assay: BMS's perspective on analyte and assay selection for ADC PK in Discovery and Development
14:15 – 14:45	Speaker: Joe Stanta (Covance) Correlation between LBA and hybrid assay: BMS's perspective on analyte and assay selection for ADC PK in Discovery and Development Speaker: Jian Wang (BMS)
14:15 - 14:45 14:45 - 15:30	Speaker: Joe Stanta (Covance) Correlation between LBA and hybrid assay: BMS's perspective on analyte and assay selection for ADC PK in Discovery and Development Speaker: Jian Wang (BMS) Coffee break & networking
14:15 - 14:45 14:45 - 15:30 15:30 - 17:00	Speaker: Joe Stanta (Covance) Correlation between LBA and hybrid assay: BMS's perspective on analyte and assay selection for ADC PK in Discovery and Development Speaker: Jian Wang (BMS) Coffee break & networking Feedback from submissions and regulatory aspects The regulatory space
14:15 – 14:45 14:45 – 15:30 15:30 – 17:00 15:30 – 16:00	Speaker: Joe Stanta (Covance) Correlation between LBA and hybrid assay: BMS's perspective on analyte and assay selection for ADC PK in Discovery and Development Speaker: Jian Wang (BMS) Coffee break & networking Feedback from submissions and regulatory aspects The regulatory space Speaker: Matthew Barfield (on behalf of the EBF) Case studies 1
14:15 – 14:45 14:45 – 15:30 15:30 – 17:00 15:30 – 16:00 16:00 - 16:30	Speaker: Joe Stanta (Covance) Correlation between LBA and hybrid assay: BMS's perspective on analyte and assay selection for ADC PK in Discovery and Development Speaker: Jian Wang (BMS) Coffee break & networking Feedback from submissions and regulatory aspects The regulatory space Speaker: Matthew Barfield (on behalf of the EBF) Case studies 1 Speaker: Surinder Kaur (Genentech) Case studies
14:15 - 14:45 14:45 - 15:30 15:30 - 17:00 15:30 - 16:00 16:00 - 16:30 16:30 - 17:00	Correlation between LBA and hybrid assay: BMS's perspective on analyte and assay selection for ADC PK in Discovery and Development Speaker: Jian Wang (BMS) Coffee break & networking Feedback from submissions and regulatory aspects The regulatory space Speaker: Matthew Barfield (on behalf of the EBF) Case studies 1 Speaker: Surinder Kaur (Genentech) Case studies Speaker: Boris Gorovits (Pfizer) Questions & Answers

The ADC training day is organized as a non-sponsored non-profit event by European Bioanalysis Forum VZW the day before the EBF Focus Workshop: Bioanalytical Strategies for Large Molecules in Modern Drug Development: LBA and LC-MS United.